2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.15 ACTN4 as a Predictive Biomarker for Osimertinib Efficacy in EGFR Mutant Non-Small Cell Lung Cancer

EP.12A.15 ACTN4 as a Predictive Biomarker for Osimertinib Efficacy in EGFR Mutant Non-Small Cell Lung Cancer

Pdf Summary

This study explores the role of Actinin-4 (ACTN4) as a predictive biomarker for the efficacy of osimertinib treatment in patients with EGFR-mutant non-small cell lung cancer (NSCLC). ACTN4, an anti-binding protein linked with tumor invasion and metastasis, may help identify patients who are likely to benefit from adjuvant chemotherapy.<br /><br />Osimertinib has been proven to prolong progression-free survival (PFS) and overall survival (OS) compared to first-generation EGFR-TKIs in previously untreated EGFR mutant NSCLC cases. However, the combination therapies, while showing longer PFS, often lead to increased adverse events (AEs). This makes patient selection based on biomarkers crucial.<br /><br />The study was retrospective, involving patients with EGFR mutant NSCLC treated with osimertinib as a first-line therapy. The main outcomes evaluated were PFS and OS, with ACTN4 expression characterized by immunohistochemistry (IHC); cases with over 30% positive tumor cells were classified as ACTN4-IHC positive.<br /><br />Findings indicate that patients with positive ACTN4 expression exhibit lower efficacy in osimertinib treatment. For ACTN4-positive patients, the median PFS was 12.3 months, compared to 16.9 months for ACTN4-negative patients, with a hazard ratio (HR) of 1.87, and a p-value of 0.035. Similarly, the median OS was shorter for ACTN4-positive patients, at 33.7 months, versus 50.7 months for ACTN4-negative patients, with an HR of 2.76 and a p-value of 0.037.<br /><br />In conclusion, ACTN4 expression can serve as a valuable biomarker for assessing the potential efficacy of osimertinib in EGFR-mutant NSCLC patients. This could guide the development of more targeted therapies and improve patient selection for treatment, potentially enhancing therapeutic outcomes.

Asset Subtitle

Takehiro Tozuka

Meta Tag

Speaker Takehiro Tozuka

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

Actinin-4

ACTN4

osimertinib

EGFR-mutant

non-small cell lung cancer

NSCLC

biomarker

progression-free survival

overall survival

immunohistochemistry